Insider Selling: Oscar Health, Inc. (NYSE:OSCR) Insider Sells $117,809.28 in Stock

Oscar Health, Inc. (NYSE:OSCR) insider Mario Schlosser sold 6,516 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $18.08, for a total value of $117,809.28. Following the transaction, the insider now directly owns 81,962 shares in the company, valued at $1,481,872.96. This trade represents a 7.36 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Oscar Health Stock Performance

OSCR opened at $16.40 on Friday. The business has a fifty day simple moving average of $17.08 and a 200 day simple moving average of $17.93. The company has a market capitalization of $4.06 billion, a PE ratio of -273.33 and a beta of 1.63. Oscar Health, Inc. has a 1 year low of $7.50 and a 1 year high of $23.79. The company has a debt-to-equity ratio of 0.26, a current ratio of 0.73 and a quick ratio of 0.73.

Oscar Health (NYSE:OSCR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.02). The firm had revenue of $2.42 billion during the quarter, compared to the consensus estimate of $2.33 billion. Oscar Health had a net margin of 0.35% and a return on equity of 2.79%. The business’s revenue for the quarter was up 68.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.29) earnings per share. Research analysts expect that Oscar Health, Inc. will post -0.01 EPS for the current year.

Analyst Ratings Changes

OSCR has been the topic of several recent analyst reports. Bank of America lowered Oscar Health from a “neutral” rating to an “underperform” rating and lowered their price target for the stock from $21.00 to $13.50 in a research report on Wednesday, November 6th. UBS Group started coverage on Oscar Health in a research note on Monday, October 7th. They set a “neutral” rating and a $23.00 target price for the company. Finally, Piper Sandler reiterated an “overweight” rating and set a $28.00 target price on shares of Oscar Health in a research note on Tuesday, September 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $22.93.

Institutional Trading of Oscar Health

Several institutional investors have recently added to or reduced their stakes in the company. Westfield Capital Management Co. LP acquired a new position in Oscar Health in the 3rd quarter valued at $27,452,000. Renaissance Technologies LLC raised its holdings in Oscar Health by 31.7% in the 2nd quarter. Renaissance Technologies LLC now owns 3,886,100 shares of the company’s stock valued at $61,478,000 after acquiring an additional 934,600 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Oscar Health in the 2nd quarter valued at $14,716,000. Bank of New York Mellon Corp raised its holdings in Oscar Health by 161.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,393,048 shares of the company’s stock valued at $22,038,000 after acquiring an additional 860,226 shares in the last quarter. Finally, Soros Fund Management LLC acquired a new position in Oscar Health in the 3rd quarter valued at $12,726,000. 75.70% of the stock is currently owned by institutional investors.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.